Venetoclax and Homoharringtonine‐Based Therapy Exhibited a Striking Response in Refractory/Relapsed Early T‐Cell Precursor Acute Lymphoblastic Leukemia
Xiang Zhang(Fujian Medical University), Wenjuan Yu(Zhejiang Cancer Hospital), Yinjun Lou(First Affiliated Hospital Zhejiang University), Qifa Liu(University of Science and Technology of China), Jian Hou(Academy of Military Medical Sciences), Shaoyuan Wang(Union Hospital), Hongsheng Zhou(Ganzhou People's Hospital), Zhenfang Liu(University of Regina), Tingbo Liu(Fujian Medical University), Xingnong Ye(First Affiliated Hospital Zhejiang University), Na Zhang(Northwest University), Meihong Luo, Ying Lu(Ningbo University), Aiping Zhang(Yangzhou University), Xiuzhen Tong(Sun Yat-sen University), Juying Wei(First Affiliated Hospital Zhejiang University), Lijing Shen(Creative Commons), Qing-Xian Bai(Xijing Hospital), Jie Jin(Beijing Institute of Technology), Hongyan Tong(First Affiliated Hospital Zhejiang University), Liping Mao(First Affiliated Hospital Zhejiang University)
Cited by 1
Related Papers
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
|International Journal of Biological Sciences|2022|350
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
The 2.5 Å Crystal Structure of the SIRT1 Catalytic Domain Bound to Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) and an Indole (EX527 Analogue) Reveals a Novel Mechanism of Histone Deacetylase Inhibition
|Journal of Medicinal Chemistry|2013|218
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
|Frontiers in Immunology|2017|209
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
|Science Translational Medicine|2016|172